CA2310510C - Procede d'identification et d'inhibition de molecules fonctionnelles d'acide nucleique dans des cellules - Google Patents
Procede d'identification et d'inhibition de molecules fonctionnelles d'acide nucleique dans des cellules Download PDFInfo
- Publication number
- CA2310510C CA2310510C CA002310510A CA2310510A CA2310510C CA 2310510 C CA2310510 C CA 2310510C CA 002310510 A CA002310510 A CA 002310510A CA 2310510 A CA2310510 A CA 2310510A CA 2310510 C CA2310510 C CA 2310510C
- Authority
- CA
- Canada
- Prior art keywords
- cells
- rna
- nucleic acid
- interest
- molecule
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 238000000034 method Methods 0.000 title claims abstract description 97
- 102000039446 nucleic acids Human genes 0.000 title claims description 59
- 108020004707 nucleic acids Proteins 0.000 title claims description 59
- 150000007523 nucleic acids Chemical class 0.000 title claims description 59
- 230000002401 inhibitory effect Effects 0.000 title description 3
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 209
- 108091034117 Oligonucleotide Proteins 0.000 claims abstract description 127
- 239000013598 vector Substances 0.000 claims abstract description 88
- 108700008625 Reporter Genes Proteins 0.000 claims abstract description 63
- 230000008685 targeting Effects 0.000 claims abstract description 47
- 102000053642 Catalytic RNA Human genes 0.000 claims abstract description 44
- 108090000994 Catalytic RNA Proteins 0.000 claims abstract description 44
- 108091092562 ribozyme Proteins 0.000 claims abstract description 44
- 238000003776 cleavage reaction Methods 0.000 claims abstract description 39
- 230000007017 scission Effects 0.000 claims abstract description 39
- 108090000621 Ribonuclease P Proteins 0.000 claims abstract description 33
- 102000004167 Ribonuclease P Human genes 0.000 claims abstract description 33
- 241000588724 Escherichia coli Species 0.000 claims abstract description 31
- 230000000692 anti-sense effect Effects 0.000 claims abstract description 15
- 230000035899 viability Effects 0.000 claims abstract description 14
- 210000004027 cell Anatomy 0.000 claims description 152
- 230000014509 gene expression Effects 0.000 claims description 112
- 102000004169 proteins and genes Human genes 0.000 claims description 106
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 55
- 108020004999 messenger RNA Proteins 0.000 claims description 38
- 241000894006 Bacteria Species 0.000 claims description 18
- 239000003795 chemical substances by application Substances 0.000 claims description 18
- 108020004566 Transfer RNA Proteins 0.000 claims description 13
- 108020001507 fusion proteins Proteins 0.000 claims description 13
- 102000037865 fusion proteins Human genes 0.000 claims description 13
- 238000004458 analytical method Methods 0.000 claims description 12
- 108020005544 Antisense RNA Proteins 0.000 claims description 10
- 239000003184 complementary RNA Substances 0.000 claims description 10
- 230000001939 inductive effect Effects 0.000 claims description 10
- 210000003527 eukaryotic cell Anatomy 0.000 claims description 9
- 230000001580 bacterial effect Effects 0.000 claims description 8
- 210000001236 prokaryotic cell Anatomy 0.000 claims description 7
- 230000002147 killing effect Effects 0.000 claims description 6
- 210000004962 mammalian cell Anatomy 0.000 claims description 6
- 230000002829 reductive effect Effects 0.000 claims description 6
- 241000187479 Mycobacterium tuberculosis Species 0.000 claims description 5
- 108020004418 ribosomal RNA Proteins 0.000 claims description 5
- 238000012216 screening Methods 0.000 claims description 5
- 241000606768 Haemophilus influenzae Species 0.000 claims description 4
- 241000202934 Mycoplasma pneumoniae Species 0.000 claims description 4
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 4
- 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 claims description 4
- 241000191967 Staphylococcus aureus Species 0.000 claims description 4
- 241000228212 Aspergillus Species 0.000 claims description 3
- 241000228197 Aspergillus flavus Species 0.000 claims description 3
- 241000222122 Candida albicans Species 0.000 claims description 3
- 241000233866 Fungi Species 0.000 claims description 3
- 241000588747 Klebsiella pneumoniae Species 0.000 claims description 3
- 241000588653 Neisseria Species 0.000 claims description 3
- 241000588770 Proteus mirabilis Species 0.000 claims description 3
- 241000588767 Proteus vulgaris Species 0.000 claims description 3
- 241000589517 Pseudomonas aeruginosa Species 0.000 claims description 3
- 241000607768 Shigella Species 0.000 claims description 3
- 241000193998 Streptococcus pneumoniae Species 0.000 claims description 3
- 241000193996 Streptococcus pyogenes Species 0.000 claims description 3
- 241001312524 Streptococcus viridans Species 0.000 claims description 3
- 230000004075 alteration Effects 0.000 claims description 3
- 230000003833 cell viability Effects 0.000 claims description 3
- 229940007042 proteus vulgaris Drugs 0.000 claims description 3
- 229940031000 streptococcus pneumoniae Drugs 0.000 claims description 3
- 108020000999 Viral RNA Proteins 0.000 claims description 2
- 230000002538 fungal effect Effects 0.000 claims description 2
- 241000193163 Clostridioides difficile Species 0.000 claims 2
- 229940095731 candida albicans Drugs 0.000 claims 2
- 239000002773 nucleotide Substances 0.000 abstract description 32
- 125000003729 nucleotide group Chemical group 0.000 abstract description 32
- 239000000758 substrate Substances 0.000 abstract description 14
- 108700039887 Essential Genes Proteins 0.000 abstract description 13
- 239000000203 mixture Substances 0.000 abstract description 9
- 239000003814 drug Substances 0.000 abstract description 6
- 230000004071 biological effect Effects 0.000 abstract description 4
- 239000003153 chemical reaction reagent Substances 0.000 abstract description 4
- 108020004513 Bacterial RNA Proteins 0.000 abstract 1
- 229920002477 rna polymer Polymers 0.000 description 100
- 235000018102 proteins Nutrition 0.000 description 74
- 108020004414 DNA Proteins 0.000 description 60
- 230000000694 effects Effects 0.000 description 31
- 239000013612 plasmid Substances 0.000 description 25
- 239000005090 green fluorescent protein Substances 0.000 description 18
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 16
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 16
- 230000004927 fusion Effects 0.000 description 16
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 15
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 15
- 230000005764 inhibitory process Effects 0.000 description 14
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 13
- 238000002474 experimental method Methods 0.000 description 13
- 230000001419 dependent effect Effects 0.000 description 11
- 238000001727 in vivo Methods 0.000 description 11
- 108010035563 Chloramphenicol O-acetyltransferase Proteins 0.000 description 10
- 102000004190 Enzymes Human genes 0.000 description 10
- 108090000790 Enzymes Proteins 0.000 description 10
- 230000003115 biocidal effect Effects 0.000 description 10
- 230000000295 complement effect Effects 0.000 description 10
- 230000006870 function Effects 0.000 description 10
- 230000012010 growth Effects 0.000 description 9
- 230000001404 mediated effect Effects 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- 108010042653 IgA receptor Proteins 0.000 description 8
- 229930182555 Penicillin Natural products 0.000 description 8
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 8
- 102100034014 Prolyl 3-hydroxylase 3 Human genes 0.000 description 8
- 238000013461 design Methods 0.000 description 8
- 231100000518 lethal Toxicity 0.000 description 8
- 230000001665 lethal effect Effects 0.000 description 8
- 229940049954 penicillin Drugs 0.000 description 8
- 238000003556 assay Methods 0.000 description 7
- 230000010076 replication Effects 0.000 description 7
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 6
- 108010052285 Membrane Proteins Proteins 0.000 description 6
- 102000018697 Membrane Proteins Human genes 0.000 description 6
- 238000010586 diagram Methods 0.000 description 6
- 238000013518 transcription Methods 0.000 description 6
- 230000035897 transcription Effects 0.000 description 6
- 241000023308 Acca Species 0.000 description 5
- 241000251131 Sphyrna Species 0.000 description 5
- 101150055766 cat gene Proteins 0.000 description 5
- 229960005091 chloramphenicol Drugs 0.000 description 5
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- 239000000411 inducer Substances 0.000 description 5
- 230000006698 induction Effects 0.000 description 5
- 230000003993 interaction Effects 0.000 description 5
- 231100000225 lethality Toxicity 0.000 description 5
- 230000009466 transformation Effects 0.000 description 5
- 239000005089 Luciferase Substances 0.000 description 4
- 238000009825 accumulation Methods 0.000 description 4
- 229960000723 ampicillin Drugs 0.000 description 4
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 4
- 238000013459 approach Methods 0.000 description 4
- 238000003491 array Methods 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 108010005774 beta-Galactosidase Proteins 0.000 description 4
- 230000002068 genetic effect Effects 0.000 description 4
- 238000009396 hybridization Methods 0.000 description 4
- 230000002779 inactivation Effects 0.000 description 4
- 210000003292 kidney cell Anatomy 0.000 description 4
- 238000007747 plating Methods 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 238000012163 sequencing technique Methods 0.000 description 4
- 230000004083 survival effect Effects 0.000 description 4
- 230000014616 translation Effects 0.000 description 4
- 108060001084 Luciferase Proteins 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 102000005936 beta-Galactosidase Human genes 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 210000000349 chromosome Anatomy 0.000 description 3
- 239000010941 cobalt Substances 0.000 description 3
- 229910017052 cobalt Inorganic materials 0.000 description 3
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 3
- 230000006735 deficit Effects 0.000 description 3
- 238000013401 experimental design Methods 0.000 description 3
- 238000010195 expression analysis Methods 0.000 description 3
- 238000010230 functional analysis Methods 0.000 description 3
- 230000009643 growth defect Effects 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 244000052769 pathogen Species 0.000 description 3
- -1 phosphorothioate diester Chemical class 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 231100000167 toxic agent Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- 239000003440 toxic substance Substances 0.000 description 3
- 238000001890 transfection Methods 0.000 description 3
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- 244000063299 Bacillus subtilis Species 0.000 description 2
- 235000014469 Bacillus subtilis Nutrition 0.000 description 2
- 241000589969 Borreliella burgdorferi Species 0.000 description 2
- 241000282693 Cercopithecidae Species 0.000 description 2
- 108091026890 Coding region Proteins 0.000 description 2
- 230000006820 DNA synthesis Effects 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 108090001102 Hammerhead ribozyme Proteins 0.000 description 2
- 241000590002 Helicobacter pylori Species 0.000 description 2
- 108091092195 Intron Proteins 0.000 description 2
- 241000606697 Rickettsia prowazekii Species 0.000 description 2
- 108010022394 Threonine synthase Proteins 0.000 description 2
- 102000005497 Thymidylate Synthase Human genes 0.000 description 2
- 241000589884 Treponema pallidum Species 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 230000003197 catalytic effect Effects 0.000 description 2
- 230000030833 cell death Effects 0.000 description 2
- 210000002421 cell wall Anatomy 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 229940023064 escherichia coli Drugs 0.000 description 2
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 229940037467 helicobacter pylori Drugs 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 210000005229 liver cell Anatomy 0.000 description 2
- 230000035800 maturation Effects 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 229940013390 mycoplasma pneumoniae Drugs 0.000 description 2
- 239000006225 natural substrate Substances 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 229940127073 nucleoside analogue Drugs 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 238000001243 protein synthesis Methods 0.000 description 2
- 230000001177 retroviral effect Effects 0.000 description 2
- 229940046939 rickettsia prowazekii Drugs 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- ALACEDPNJIAQMY-UHFFFAOYSA-N 1,3-dihydroxypyrimidine-2,4-dione Chemical compound ON1C=CC(=O)N(O)C1=O ALACEDPNJIAQMY-UHFFFAOYSA-N 0.000 description 1
- OPIFSICVWOWJMJ-AEOCFKNESA-N 5-bromo-4-chloro-3-indolyl beta-D-galactoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=CNC2=CC=C(Br)C(Cl)=C12 OPIFSICVWOWJMJ-AEOCFKNESA-N 0.000 description 1
- SEHFUALWMUWDKS-UHFFFAOYSA-N 5-fluoroorotic acid Chemical compound OC(=O)C=1NC(=O)NC(=O)C=1F SEHFUALWMUWDKS-UHFFFAOYSA-N 0.000 description 1
- 241000242764 Aequorea victoria Species 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 108020004491 Antisense DNA Proteins 0.000 description 1
- 241000207208 Aquifex Species 0.000 description 1
- 241000893512 Aquifex aeolicus Species 0.000 description 1
- 241000194103 Bacillus pumilus Species 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 241000894010 Buchnera aphidicola Species 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 241000606161 Chlamydia Species 0.000 description 1
- 241000606153 Chlamydia trachomatis Species 0.000 description 1
- 241000282552 Chlorocebus aethiops Species 0.000 description 1
- 241000193403 Clostridium Species 0.000 description 1
- 241000229118 Clostridium sp. MCF-1 Species 0.000 description 1
- 241000186226 Corynebacterium glutamicum Species 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- DYDCUQKUCUHJBH-UWTATZPHSA-N D-Cycloserine Chemical class N[C@@H]1CONC1=O DYDCUQKUCUHJBH-UWTATZPHSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-UWTATZPHSA-N D-alanine Chemical compound C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 101710137619 DNA gyrase inhibitor Proteins 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 206010011878 Deafness Diseases 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 241001646716 Escherichia coli K-12 Species 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- CWYNVVGOOAEACU-UHFFFAOYSA-N Fe2+ Chemical compound [Fe+2] CWYNVVGOOAEACU-UHFFFAOYSA-N 0.000 description 1
- 108700007698 Genetic Terminator Regions Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 241001235200 Haemophilus influenzae Rd KW20 Species 0.000 description 1
- 241000724709 Hepatitis delta virus Species 0.000 description 1
- 102000037862 Ion Transporter Human genes 0.000 description 1
- 108091006671 Ion Transporter Proteins 0.000 description 1
- 241000588915 Klebsiella aerogenes Species 0.000 description 1
- 241000186673 Lactobacillus delbrueckii Species 0.000 description 1
- 244000132194 Lactobacillus helveticus subsp jugurti Species 0.000 description 1
- 235000005448 Lactobacillus helveticus subsp jugurti Nutrition 0.000 description 1
- 241000186604 Lactobacillus reuteri Species 0.000 description 1
- 241001492414 Marina Species 0.000 description 1
- MSFSPUZXLOGKHJ-UHFFFAOYSA-N Muraminsaeure Natural products OC(=O)C(C)OC1C(N)C(O)OC(CO)C1O MSFSPUZXLOGKHJ-UHFFFAOYSA-N 0.000 description 1
- 241000204051 Mycoplasma genitalium Species 0.000 description 1
- 241000432072 Mycoplasma pneumoniae M129 Species 0.000 description 1
- 241000244206 Nematoda Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 241000606856 Pasteurella multocida Species 0.000 description 1
- 108010013639 Peptidoglycan Proteins 0.000 description 1
- 108010093965 Polymyxin B Proteins 0.000 description 1
- 241000605860 Prevotella ruminicola Species 0.000 description 1
- 108010001267 Protein Subunits Proteins 0.000 description 1
- 102000002067 Protein Subunits Human genes 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 102000009661 Repressor Proteins Human genes 0.000 description 1
- 108010034634 Repressor Proteins Proteins 0.000 description 1
- 241000589187 Rhizobium sp. Species 0.000 description 1
- 241001148569 Rhodothermus Species 0.000 description 1
- 241000192031 Ruminococcus Species 0.000 description 1
- 101150054830 S100A6 gene Proteins 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 1
- 241001135266 Salmonella enterica subsp. enterica serovar Berta Species 0.000 description 1
- 241000242583 Scyphozoa Species 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- 241000193985 Streptococcus agalactiae Species 0.000 description 1
- 244000057717 Streptococcus lactis Species 0.000 description 1
- 235000014897 Streptococcus lactis Nutrition 0.000 description 1
- 241000187433 Streptomyces clavuligerus Species 0.000 description 1
- 241000509474 Streptomyces flavovirens Species 0.000 description 1
- 241000187411 Streptomyces phaeochromogenes Species 0.000 description 1
- 241000272534 Struthio camelus Species 0.000 description 1
- 241000192593 Synechocystis sp. PCC 6803 Species 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 241000520244 Tatumella citrea Species 0.000 description 1
- 241000223892 Tetrahymena Species 0.000 description 1
- 241000186064 Trueperella pyogenes Species 0.000 description 1
- 244000000188 Vaccinium ovalifolium Species 0.000 description 1
- 241000726445 Viroids Species 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 108091005971 Wild-type GFP Proteins 0.000 description 1
- 241000607734 Yersinia <bacteria> Species 0.000 description 1
- 241000588902 Zymomonas mobilis Species 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 125000000266 alpha-aminoacyl group Chemical group 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 229940126573 antibacterial therapeutic Drugs 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000003816 antisense DNA Substances 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 208000019065 cervical carcinoma Diseases 0.000 description 1
- 239000013043 chemical agent Substances 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 229940038705 chlamydia trachomatis Drugs 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 229910001429 cobalt ion Inorganic materials 0.000 description 1
- XLJKHNWPARRRJB-UHFFFAOYSA-N cobalt(2+) Chemical compound [Co+2] XLJKHNWPARRRJB-UHFFFAOYSA-N 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000010432 diamond Substances 0.000 description 1
- 231100000676 disease causative agent Toxicity 0.000 description 1
- ZWAOHEXOSAUJHY-ZIYNGMLESA-N doxifluridine Chemical compound O[C@@H]1[C@H](O)[C@@H](C)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ZWAOHEXOSAUJHY-ZIYNGMLESA-N 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 229940092559 enterobacter aerogenes Drugs 0.000 description 1
- ODKNJVUHOIMIIZ-RRKCRQDMSA-N floxuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ODKNJVUHOIMIIZ-RRKCRQDMSA-N 0.000 description 1
- 238000002189 fluorescence spectrum Methods 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 238000011331 genomic analysis Methods 0.000 description 1
- 239000002271 gyrase inhibitor Substances 0.000 description 1
- 229940047650 haemophilus influenzae Drugs 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000013383 initial experiment Methods 0.000 description 1
- 238000013101 initial test Methods 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 229940001882 lactobacillus reuteri Drugs 0.000 description 1
- GZQKNULLWNGMCW-PWQABINMSA-N lipid A (E. coli) Chemical compound O1[C@H](CO)[C@@H](OP(O)(O)=O)[C@H](OC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC)[C@@H](NC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCC)[C@@H]1OC[C@@H]1[C@@H](O)[C@H](OC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](NC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](OP(O)(O)=O)O1 GZQKNULLWNGMCW-PWQABINMSA-N 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000005265 lung cell Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000002906 microbiologic effect Effects 0.000 description 1
- 239000006151 minimal media Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- MHWLWQUZZRMNGJ-UHFFFAOYSA-N nalidixic acid Chemical compound C1=C(C)N=C2N(CC)C=C(C(O)=O)C(=O)C2=C1 MHWLWQUZZRMNGJ-UHFFFAOYSA-N 0.000 description 1
- 229960000210 nalidixic acid Drugs 0.000 description 1
- 230000018791 negative regulation of catalytic activity Effects 0.000 description 1
- 229940051027 pasteurella multocida Drugs 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 150000004713 phosphodiesters Chemical class 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 229920000024 polymyxin B Polymers 0.000 description 1
- 229960005266 polymyxin b Drugs 0.000 description 1
- 235000004252 protein component Nutrition 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000006152 selective media Substances 0.000 description 1
- 210000000717 sertoli cell Anatomy 0.000 description 1
- 239000013605 shuttle vector Substances 0.000 description 1
- 238000007860 single-cell PCR Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 208000006379 syphilis Diseases 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 230000014621 translational initiation Effects 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6897—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids involving reporter genes operably linked to promoters
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
- C12N2310/126—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes involving RNAse P
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- General Health & Medical Sciences (AREA)
- Analytical Chemistry (AREA)
- Immunology (AREA)
- Plant Pathology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
L'invention concerne deux méthodologies. Dans la première, un moyen pour identifier rapidement et efficacement des gènes fonctionnels et essentiels est prévu. Dans la deuxième, un moyen pour produire des molécules nucléiques biologiquement actives (ribozymes, séquences guides externes et antisens) qui peuvent être utilisées pour l'inactivation de gènes fonctionnels. Dans le premier procédé, une banque de séquences guides externes (EGS) à base de toutes les compositions possibles connues est préparée. Dans un mode de réalisation préféré, les EGS constituent douze ou treize mères pour cibler l'RNase bactérien pour le clivage d'un substrat. Cette banque est ajoutée à des cellules contenant les gènes à cribler, par exemple, E. coli. Les cellules dans lesquelles EGS provoque une perte de viabilité, ou d'autre phénotype, sont identifiées. La ou les EGS responsables de la perte de viabilité sont analysées, et l'information relative à la séquence résultante est utilisée pour l'identification du gène dans des séquences génomiques connues. Dans le deuxième procédé, les molécules nucléotidiques ayant une activité biologique optimale, par exemple, dirigeant le clivage d'un gène particulier par RNase P, sont rapidement identifiées au moyen d'un vecteur comprenant deux gènes reporters, le premier en phase avec le gène en question et le deuxième permettant de vérifier que le vecteur est présent dans une cellule ou facilitant la sélection de cellules contenant le vecteurs. Les cellules dans lesquelles le gène en question est clivé par la molécule oligonucléotidique fonctionnelle peuvent ensuite être identifiées en fonction du gène reporter 1. Les molécules oligonucléotidiques fonctionnelles responsables sont ensuite isolées et caractérisées. Lesdits procédés constituent des outils puissants pour l'identification de gènes essentiels dont la séquence est connue seulement comme faisant partie intégrante d'un génome à fonction inconnue, ainsi que des moyens d'identification de molécules oligonucléotidiques fonctionnelles, utiles comme réactifs diagnostiques et comme agents thérapeutiques.
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/976,220 US6013447A (en) | 1997-11-21 | 1997-11-21 | Random intracellular method for obtaining optimally active nucleic acid molecules |
| US976,220 | 1997-11-21 | ||
| US7985198P | 1998-03-30 | 1998-03-30 | |
| US60/079,851 | 1998-03-30 | ||
| PCT/US1998/024854 WO1999027135A2 (fr) | 1997-11-21 | 1998-11-20 | Procede d'identification et d'inhibition de molecules fonctionnelles d'acide nucleique dans des cellules |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2310510A1 CA2310510A1 (fr) | 1999-06-03 |
| CA2310510C true CA2310510C (fr) | 2007-04-17 |
Family
ID=26762503
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002310510A Expired - Fee Related CA2310510C (fr) | 1997-11-21 | 1998-11-20 | Procede d'identification et d'inhibition de molecules fonctionnelles d'acide nucleique dans des cellules |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP1032707A2 (fr) |
| JP (1) | JP2001524317A (fr) |
| AU (1) | AU732321B2 (fr) |
| CA (1) | CA2310510C (fr) |
| WO (1) | WO1999027135A2 (fr) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999028508A1 (fr) * | 1997-12-04 | 1999-06-10 | Smithkline Beecham Corporation | Procede mettant en oeuvre des sequences antisens d'expression pour produire des cellules mutantes exprimees de maniere conditionnelle |
| AU4186600A (en) * | 1999-03-31 | 2000-10-16 | Rosetta Inpharmatics, Inc. | Essential genes of yeast as targets for antifungal agents, herbicides, insecticides and anti-proliferation drugs |
| GB9912965D0 (en) * | 1999-06-03 | 1999-08-04 | Oxford Biomedica Ltd | In vivo selection method |
| GB9929744D0 (en) * | 1999-12-17 | 2000-02-09 | Univ Nottingham | Modifying micro-organisms |
| AU2368201A (en) * | 1999-12-23 | 2001-07-09 | Xantos Biomedicine Ag | Screening method for nucleic acids |
| AU2008202554C1 (en) * | 2001-02-23 | 2011-07-07 | Dsm Ip Assets B.V. | Novel genes encoding novel proteolytic enzymes |
| US20130244905A1 (en) * | 2010-07-06 | 2013-09-19 | Ed Grabczyk | Reporter for RNA Polymerase II Termination |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5168053A (en) * | 1989-03-24 | 1992-12-01 | Yale University | Cleavage of targeted RNA by RNAase P |
| AU669367B2 (en) * | 1992-04-28 | 1996-06-06 | Yale University | Targeted cleavage of RNA using eukaryotic ribonuclease P and external guide sequence |
| WO1994013791A1 (fr) * | 1992-12-04 | 1994-06-23 | Innovir Laboratories, Inc. | Acide nucleique regulable a usage therapeutique et procedes d'utilisation associes |
| AU4961996A (en) * | 1994-12-14 | 1996-07-03 | Innovir Laboratories, Inc. | Ribozyme-mediated inactivation of leukemia-associated rna |
| EP0850318A1 (fr) * | 1995-09-13 | 1998-07-01 | Chiron Corporation | Procede et produit d'assemblage pour la recherche d'inhibiteurs d'activation de la transcription |
| US5877162A (en) * | 1996-03-14 | 1999-03-02 | Innovir Laboratories, Inc. | Short external guide sequences |
| AU4071197A (en) * | 1996-08-16 | 1998-03-06 | Yale University | Phenotypic conversion of drug-resistant bacteria to drug-sensitivity |
| US6605429B1 (en) * | 1997-01-23 | 2003-08-12 | Immusol, Incorporated | Gene functional analysis and discovery using randomized or target-specific ribozyme gene vector libraries |
-
1998
- 1998-11-20 CA CA002310510A patent/CA2310510C/fr not_active Expired - Fee Related
- 1998-11-20 JP JP2000522276A patent/JP2001524317A/ja active Pending
- 1998-11-20 EP EP98959542A patent/EP1032707A2/fr not_active Withdrawn
- 1998-11-20 AU AU15323/99A patent/AU732321B2/en not_active Ceased
- 1998-11-20 WO PCT/US1998/024854 patent/WO1999027135A2/fr not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| AU732321B2 (en) | 2001-04-12 |
| WO1999027135A2 (fr) | 1999-06-03 |
| WO1999027135A3 (fr) | 1999-07-29 |
| JP2001524317A (ja) | 2001-12-04 |
| CA2310510A1 (fr) | 1999-06-03 |
| EP1032707A2 (fr) | 2000-09-06 |
| AU1532399A (en) | 1999-06-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN113646434B (zh) | 使用加标签的向导rna构建体进行高效基因筛选的组合物和方法 | |
| EP3752647B1 (fr) | Enregistreurs de données cellulaires et leurs utilisations | |
| Xu et al. | A CRISPR/Cas13-based approach demonstrates biological relevance of vlinc class of long non-coding RNAs in anticancer drug response | |
| US6248525B1 (en) | Method for identifying essential or functional genes | |
| CA2496821C (fr) | Selection et isolement de cellules vivantes au moyen de sondes liant l'arnm | |
| US6013447A (en) | Random intracellular method for obtaining optimally active nucleic acid molecules | |
| US7524653B2 (en) | Small interfering RNA libraries and methods of synthesis and use | |
| Stumpf et al. | Polyphosphate kinase regulates error‐prone replication by DNA polymerase IV in Escherichia coli | |
| CN113631700B (zh) | 用于鉴定tau接种或聚集的基因修饰因子的CRISPR/Cas筛选平台 | |
| Lee et al. | Insertion-duplication mutagenesis in Streptococcus pneumoniae: targeting fragment length is a critical parameter in use as a random insertion tool | |
| CA2310510C (fr) | Procede d'identification et d'inhibition de molecules fonctionnelles d'acide nucleique dans des cellules | |
| Slechta et al. | Evidence that selected amplification of a bacterial lac frameshift allele stimulates Lac+ reversion (adaptive mutation) with or without general hypermutability | |
| US20020002278A1 (en) | Random intracellular method for obtaining optimally active nucleic acid molecules | |
| Delaleau et al. | Comprehensive mapping of transcription terminator Rho utilization (Rut) sites across the Bacillus subtilis genome | |
| EP1184462A2 (fr) | Identification de cibles de composés à activité anti-microbienne | |
| US20020058287A1 (en) | Novel small nuclear RNA vectors and uses therefor | |
| AU2011203213A1 (en) | Selection and Isolation of Living Cells Using mRNA-Binding Probes | |
| Ellis et al. | A multiplex CRISPR interference tool for virulence gene interrogation in an intracellular pathogen | |
| US20050136393A1 (en) | Oligodoxynucleotide (ODN) libraries, their use in screening for antibacterial agents, and catalytic ODN sequence for use as an antibacterial agent | |
| AU2008202162B2 (en) | Selection and Isolation of Living Cells Using mRNA-Binding Probes | |
| Billingsley et al. | Nucleic Acid Hybridization Techniques and Neurotoxicity Assessment | |
| Winkler | Regulatory RNAs at the Heart of Sugar Metabolism: New Mechanisms and Novel Discoveries | |
| HK1079238B (en) | Selection and isolation of living cells using rna-binding probes | |
| HK1146637B (en) | Selection and isolation of living cells using mrna-binding probes | |
| HK1146637A1 (en) | Selection and isolation of living cells using mrna-binding probes |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKLA | Lapsed |
Effective date: 20141120 |